Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
idiopathic pulmonary fibrosis
Biotech
Endeavor Hedgehog inhibitor has potential to shake up IPF space
Endeavor solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could put IPF into reverse.
James Waldron
Oct 8, 2026 9:50am
Analysts unshaken by patient death in BMS lung fibrosis trial
Oct 1, 2026 10:22am
With $30M, Oorja Bio breathes new life into fibrosis candidate
May 20, 2026 10:31am
Avalyn aims for $182M IPO to fund ph. 3 trials of lung drugs
Apr 24, 2026 7:08am
Avalyn plans IPO to fund ph. 3 trials of inhaled lung drugs
Apr 9, 2026 4:13am
Roche drops $100M Kiniksa fibrosis drug from ph. 2 pipeline
Jan 29, 2026 6:29am
